News

A study comparing two continuous treatment regimens of tobramycin inhalation (Tobi) for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) found that administration of both once a day and twice daily treatment was safe and well-tolerated. The study, titled “Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation…

Researchers identified a novel, rare mutation causing cystic fibrosis (CF) in a pediatric African-American patient. The mutation, however, was found to be responsive to the CFTR corrector VX-809, therefore identifying potential personalized therapeutics. The study, “c.3623G > A mutation encodes a CFTR protein with impaired channel function,” was published…

The University of Iowa (UI) Research Foundation recently announced it had struck a license and sponsored research agreement with Pfizer to support the development of a potential gene therapy for cystic fibrosis (CF). The research will be performed in the the laboratories of Profs. John Engelhardt and Ziying Yan. Both…

Alegeus recently announced that it will donate a total of $20,000 to three charities — including the Cystic Fibrosis Foundation — as part of its 2015 holiday giving program. Instead of handing out corporate gifts and holiday cards, Alegeus opted to let employees chose charities to support. Votes given to the three…

Vertex Pharmaceuticals Incorporated recently announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) to its supplemental New Drug Application (sNDA) for Kalydeco (ivacaftor) as a treatment for cystic fibrosis patients ages 2 and older with one of 23 residual function mutations in the cystic fibrosis transmembrane conductance…

Proteostasis Therapeutics, Inc., announced that it recently received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for PTI-428, an investigational oral treatment for cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in a disruption of ion…

Arch Biopartners, Inc, announced that it recently submitted an orphan drug designation application to the European Medicines Authority (EMA) for its product AB569, a potential treatment of pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF). The EMA is now reviewing the application, and the Committee for Orphan Medicinal Products…

Three Case Western Reserve University faculty members recently received significant funding from the National Center for Accelerated Innovation (NCAI) to conduct projects and develop novel technologies targeting sickle cell anemia, malaria, and cystic fibrosis (CF). NCAI supports new technologies and innovative products that have been targeted as…

Researchers at Stanford University School of Medicine developed a highly sensitive, specific, rapid and cost-effective assay for cystic fibrosis (CF) screening in newborn babies. The research article detailing the development and performance of the new assay, “Next-Generation Molecular Testing of Newborn Dried Blood Spots for Cystic Fibrosis,” was…

University of Iowa researchers appear to have discovered the long-awaited answer as to why mice that carry cystic fibrosis (CF) mutations do not develop the serious lung disease observed in human CF patients. Their work also revealed a new therapeutic target that might stop CF progression. The study, “Airway acidification initiates host defense abnormalities…